Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kangmei Pharmaceutical Co., Ltd. (600518.SS)
Shenzhen, GD, CN
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, medical e-commerce, mobile medical care, etc. Kangmei Pharmaceutical Co., Ltd. was founded in 1997 and is based in Shenzhen, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.16% | -0.58% | -3.93% | -10.00% | -16.99% | -10.47% | -14.07% | -23.32% | -15.76% | -88.79% | +49.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+1.1% Q1'26: -16.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+16.7% Q1'26: -266.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-8.2% Q1'26: -6.5% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-3.3% Q1'26: -1.2% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%-1.6% Q1'26: -0.8% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+3.3% Q1'26: +15.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.94× ★ Q1'26: -2.95× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
|---|---|
| Revenue |
5.41B
est: 45.48B (-88.1%)
|
| EBITDA |
-26.15B
est: -15.50B (-68.7%)
|
| EBIT |
-26.79B
est: -18.42B (-45.4%)
|
| Net Income |
-31.08B
|
| SGA |
1.94B
est: 11.88B (-83.7%)
|
| EPS |
-6.30
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.03% | 24.7K | 0.55% |
| 2 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 5.4K | 0.15% |
| 3 | Franklin FTSE China ETF FLCH | 0.01% | 21.2K | 0.19% |
| 4 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 86.2K | 0.19% |
| 5 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 10.7K | 0.58% |
| 6 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 149.1K | 0.17% |
| 7 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 149.1K | 0.17% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 54.9K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 24.4K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.71M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guibo Gong | Deputy GM & Chief Financial Officer | — | male |
| Guoxiong Ou | GM & Director | — | male |
| Jin Jin Zhang | Assistant to General Manager | — | female |
| Li Feng Tian | Accounting Supervisor & Head of Accounting Agency | — | — |
| Qiyun Chen | Deputy General Manager | — | male |
| Xinquan Liu | Deputy General Manager | — | male |
| Yunfeng Zhou | Deputy GM, Secretary to the Board & Director | — | male |
| Zebin Li | Assistant to General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600518.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
